Reliability Estimation Based on System Data with an Unknown Load Share Rule

We consider a multicomponent load-sharing system in which the failure rate of a given component depends on the set of working components at any given time. Such systems can arise in software reliability models and in multivariate failure-time models in biostatistics, for example. A load-share rule dictates how stress or load is redistributed to the surviving components after a component fails within the system. In this paper, we assume the load share rule is unknown and derive methods for statistical inference on load-share parameters based on maximum likelihood. Components with (individual) constant failure rates are observed in two environments: (1) the system load is distributed evenly among the working components, and (2) we assume only the load for each working component increases when other components in the system fail. Tests for these special load-share models are investigated.     

Treatment effect measures under nonproportional hazards

In a clinical trial with a time-to-event endpoint the treatment effect can be measured in various ways. Under proportional hazards all reasonable measures (such as the hazard ratio and the difference in restricted mean survival time) are consistent in the following sense: Take any control group survival distribution such that the hazard rate remains above zero; if there is no benefit by any measure there is no benefit by all measures, and as the magnitude of treatment benefit increases by any measure it increases by all measures. Under nonproportional hazards, however, survival curves can cross, and the direction of the effect for any pair of measures can be inconsistent. In this paper we critically evaluate a variety of treatment effect measures in common use and identify flaws with them. In particular, we demonstrate that a treatment's benefit has two distinct and independent dimensions which can be measured by the difference in the survival rate at the end of follow-up and the difference in restricted mean survival time, and that commonly used measures do not adequately capture both dimensions. We demonstrate that a generalized hazard difference, which can be estimated by the difference in exposure-adjusted subject incidence rates, captures both dimensions, and that its inverse, the number of patient-years of follow-up that results in one fewer event (the NYNT), is an easily interpretable measure of the magnitude of clinical benefit.     

Bias‐reduced marginal Akaike information criteria based on a Monte Carlo method for linear mixed‐effects models

In linear mixed‐effects (LME) models, if a fitted model has more random‐effect terms than the true model, a regularity condition required in the asymptotic theory may not hold. In such cases, the marginal Akaike information criterion (AIC) is positively biased for (?2) times the expected log‐likelihood. The asymptotic bias of the maximum log‐likelihood as an estimator of the expected log‐likelihood is evaluated for LME models with balanced design in the context of parameter‐constrained models. Moreover, bias‐reduced marginal AICs for LME models based on a Monte Carlo method are proposed. The performance of the proposed criteria is compared with existing criteria by using example data and by a simulation study. It was found that the bias of the proposed criteria was smaller than that of the existing marginal AIC when a larger model was fitted and that the probability of choosing a smaller model incorrectly was decreased.     

股票期权和限制性股票激励制度的比较与选择

股票期权与限制性股票是我国上市公司股权激励的两种主要形式,它们在授予(行权)价格、解锁期、授予数量、收益与风险大小上存在差别。经过比较分析认为,股票期权适合处于成长初期或扩张期的企业,限制性股票则更适合已迈入成熟阶段的大型企业。     

Quantifying treatment differences in confirmatory trials under non-proportional hazards

Proportional hazards are a common assumption when designing confirmatory clinical trials in oncology. With the emergence of immunotherapy and novel targeted therapies, departure from the proportional hazard assumption is not rare in nowadays clinical research. Under non-proportional hazards, the hazard ratio does not have a straightforward clinical interpretation, and the log-rank test is no longer the most powerful statistical test even though it is still valid. Nevertheless, the log-rank test and the hazard ratio are still the primary analysis tools, and traditional approaches such as sample size increase are still proposed to account for the impact of non-proportional hazards. The weighed log-rank test and the test based on the restricted mean survival time (RMST) are receiving a lot of attention as a potential alternative to the log-rank test. We conduct a simulation study comparing the performance and operating characteristics of the log-rank test, the weighted log-rank test and the test based on the RMST, including a treatment effect estimation, under different non-proportional hazards patterns. Results show that, under non-proportional hazards, the hazard ratio and weighted hazard ratio have no straightforward clinical interpretation whereas the RMST ratio can be interpreted regardless of the proportional hazards assumption. In terms of power, the RMST achieves a similar performance when compared to the log-rank test.     

论中小企业集群发展的制约因素及对策

中小企业集群作为一种特殊的产业组织形式,近年来在世界范围内逐渐显现出强大的生命力和经济活力,这也是我国中小企业发展的必然路径。中小企业集群在发展中受很多因素影响和制约,对其加以系统分析和研究,并找出解决的措施,有利于推进中小企业集群的发展。     

论我国经济性裁员制度的完善

经济性裁员制度赋予用人单位以较宽泛的劳动关系解除权 ,它是用人单位用人自主权的体现。通过裁员 ,用人单位可在一定程度上缓解经营困境 ,提高市场的竞争力。但如果用人单位滥用该权利 ,则会造成大量的劳动者失业 ,侵犯劳动者的合法权益 ,对国家、社会的稳定带来不利的影响。我国加入WTO后各企业的裁员行为将更加明显 ,更加频繁。因此我们有必要参照他国的做法并结合我国的实际对我国的经济性裁员制度予以完善。     

Simulation assessments of statistical aspects of bioequivalence in the pharmaceutical industry

An Erratum has been published for this article in Pharmaceutical Statistics 2004; 3(3): 232 Since the early 1990s, average bioequivalence (ABE) has served as the international standard for demonstrating that two formulations of drug product will provide the same therapeutic benefit and safety profile. Population (PBE) and individual (IBE) bioequivalence have been the subject of intense international debate since methods for their assessment were proposed in the late 1980s. Guidance has been proposed by the Food and Drug Administration (FDA) for the implementation of these techniques in the pioneer and generic pharmaceutical industries. Hitherto no consensus among regulators, academia and industry has been established on the use of the IBE and PBE metrics. The need for more stringent bioequivalence criteria has not been demonstrated, and it is known that the PBE and IBE criteria proposed by the FDA are actually less stringent under certain conditions. The statistical properties of method of moments and restricted maximum likelihood modelling in replicate designs will be summarized, and the application of these techniques in the assessment of ABE, IBE and PBE will be considered based on a database of 51 replicate design studies and using simulation. Copyright © 2004 John Wiley & Sons, Ltd.     

Variance Estimation in Spatial Regression Using a Non-parametric Semivariogram Based on Residuals

Abstract.  The empirical semivariogram of residuals from a regression model with stationary errors may be used to estimate the covariance structure of the underlying process. For prediction (kriging) the bias of the semivariogram estimate induced by using residuals instead of errors has only a minor effect because the bias is small for small lags. However, for estimating the variance of estimated regression coefficients and of predictions, the bias due to using residuals can be quite substantial. Thus we propose a method for reducing this bias. The adjusted empirical semivariogram is then isotonized and made conditionally negative-definite and used to estimate the variance of estimated regression coefficients in a general estimating equations setup. Simulation results for least squares and robust regression show that the proposed method works well in linear models with stationary correlated errors.